MXPA06001263A - Derivados de nitrooxi de losartan, valsartan, candesartan, telmisartan, eprosartan y olmesartan como bloqueadores de receptor de angiotensina ii para el tratamiento de enfermedades cardiovasculares. - Google Patents

Derivados de nitrooxi de losartan, valsartan, candesartan, telmisartan, eprosartan y olmesartan como bloqueadores de receptor de angiotensina ii para el tratamiento de enfermedades cardiovasculares.

Info

Publication number
MXPA06001263A
MXPA06001263A MXPA06001263A MXPA06001263A MXPA06001263A MX PA06001263 A MXPA06001263 A MX PA06001263A MX PA06001263 A MXPA06001263 A MX PA06001263A MX PA06001263 A MXPA06001263 A MX PA06001263A MX PA06001263 A MXPA06001263 A MX PA06001263A
Authority
MX
Mexico
Prior art keywords
angiotensin
receptor blocker
derivatives
ono2
renal
Prior art date
Application number
MXPA06001263A
Other languages
English (en)
Inventor
Nicoletta Almirante
Original Assignee
Nicox Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicox Sa filed Critical Nicox Sa
Publication of MXPA06001263A publication Critical patent/MXPA06001263A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/20—Two benzimidazolyl-2 radicals linked together directly or via a hydrocarbon or substituted hydrocarbon radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Abstract

Derivados de nitrooxi de los bloqueadores de receptor de angiotensina II losartan, valsartan, candesartan, telmisartan, eprosartan y olmesartan y compuestos relacionados de la formual (i): R(Y-ONO2)s, en donde R es de la formula (II) o (III); R0 es v.gr., y R1 es (IIa), (IIb), (IIc), (IId) o (IIe).
MXPA06001263A 2003-07-31 2004-07-20 Derivados de nitrooxi de losartan, valsartan, candesartan, telmisartan, eprosartan y olmesartan como bloqueadores de receptor de angiotensina ii para el tratamiento de enfermedades cardiovasculares. MXPA06001263A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03102379 2003-07-31
PCT/EP2004/051550 WO2005011646A2 (en) 2003-07-31 2004-07-20 Nitrooxy derivatives of losartan, valsatan, candesartan, telmisartan, eprosartan and olmesartan as angiotensin-ii receptor blockers for the treatment of cardiovascular diseases

Publications (1)

Publication Number Publication Date
MXPA06001263A true MXPA06001263A (es) 2006-04-11

Family

ID=34112476

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06001263A MXPA06001263A (es) 2003-07-31 2004-07-20 Derivados de nitrooxi de losartan, valsartan, candesartan, telmisartan, eprosartan y olmesartan como bloqueadores de receptor de angiotensina ii para el tratamiento de enfermedades cardiovasculares.

Country Status (30)

Country Link
US (1) US20060276523A1 (es)
EP (1) EP1653950B1 (es)
JP (1) JP2007500684A (es)
KR (1) KR20060056352A (es)
CN (1) CN100496490C (es)
AR (1) AR045145A1 (es)
AT (1) ATE383155T1 (es)
AU (1) AU2004260830B2 (es)
BR (1) BRPI0413028A (es)
CA (1) CA2534451A1 (es)
CY (1) CY1110447T1 (es)
DE (1) DE602004011230T2 (es)
DK (1) DK1653950T3 (es)
EC (1) ECSP066334A (es)
ES (1) ES2299861T3 (es)
HK (1) HK1095093A1 (es)
HR (1) HRP20060084A2 (es)
IL (1) IL172703A0 (es)
IS (1) IS2534B (es)
MA (1) MA27987A1 (es)
MX (1) MXPA06001263A (es)
NO (1) NO20060900L (es)
NZ (1) NZ544463A (es)
PL (2) PL379420A1 (es)
PT (1) PT1653950E (es)
RU (1) RU2374240C2 (es)
SI (1) SI1653950T1 (es)
UA (1) UA87983C2 (es)
WO (1) WO2005011646A2 (es)
ZA (1) ZA200600856B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2574666A1 (en) * 2004-07-20 2006-01-26 Nicox S.A. Process for preparing nitrooxy esters, nitrooxy thioesters, nitrooxy carbonates and nitrooxy thiocarbonates, intermediates useful in said process and preparation thereof
WO2006079610A1 (en) * 2005-01-31 2006-08-03 Nicox S.A. Nitrooxy sartan derivatives as angiotensin ii receptor blockers for the treatment of cardiovascular and inflammatory diseases
CN101024643A (zh) 2006-02-20 2007-08-29 上海艾力斯医药科技有限公司 咪唑－5－羧酸类衍生物、制备方法及其应用
TW200821303A (en) * 2006-08-08 2008-05-16 Speedel Experimenta Ag Organic compounds
CA2668744C (en) 2006-11-17 2015-09-15 Queen's University At Kingston Compounds and methods for treating protein folding disorders
AU2006351517B8 (en) * 2006-12-06 2012-01-19 Shenzhen Salubris Pharmaceuticals Co., Ltd. The salts of imidazol-5-carboxylic acid derivatives, preparation methods and use thereof
CA2671421A1 (en) * 2006-12-13 2008-06-26 Merck & Co., Inc. Nitroderivatives as angiotensin ii receptor antagonists
TW200831079A (en) 2006-12-13 2008-08-01 Merck & Co Inc Angiotensin II receptor antagonists
CN101214242A (zh) 2007-01-05 2008-07-09 上海艾力斯医药科技有限公司 新的药用组合物
EP1980559A1 (en) * 2007-04-10 2008-10-15 CTG Pharma S.r.l. Cardiovascular agents
CN101317842A (zh) 2007-06-07 2008-12-10 上海艾力斯医药科技有限公司 一种咪唑-5-羧酸衍生物的治疗用途
CN101407511B (zh) * 2007-10-11 2013-01-09 上海艾力斯生物医药有限公司 一种结晶型的咪唑-5-羧酸衍生物
AR069340A1 (es) * 2007-11-26 2010-01-13 Merck & Co Inc Antagonistas del receptor de angiotensina ii
ES2394589T3 (es) 2007-12-14 2013-02-04 Aerodesigns, Inc Suministro de productos alimenticios transformables en aerosol
EP2244575B1 (en) * 2008-01-24 2013-07-17 Merck Sharp & Dohme Corp. Angiotensin ii receptor antagonists
EP2250168B1 (en) * 2008-02-08 2014-11-19 Merck Sharp & Dohme Corp. Angiotensin ii receptor antagonists
US20110052674A1 (en) * 2008-02-26 2011-03-03 Merck Sharp & Dohme Corp. Angiotensin ii receptor blocker derivatives
CA2712689A1 (en) * 2008-02-26 2009-09-03 Nicoletta Almirante Angiotensin ii receptor antagonists
EP2291076A4 (en) * 2008-05-15 2012-03-21 Merck Sharp & Dohme Angiotensin-II Receptor Antagonists
CN101596189A (zh) * 2008-06-05 2009-12-09 上海艾力斯生物医药有限公司 含有咪唑-5-羧酸类衍生物的药用组合物
US20110077279A1 (en) * 2008-06-09 2011-03-31 Nicoletta Almirante Angiotensin ii receptor antagonists
AR073259A1 (es) * 2008-07-29 2010-10-28 Merck & Co Inc Derivados de furosemida utiles como diureticos
WO2010015447A1 (en) * 2008-08-08 2010-02-11 Nicox S.A. Angiotensin ii receptor antagonists
EP2194048A1 (en) 2008-12-02 2010-06-09 Dirk Sartor Nitrate esters for the treatment of vascular and metabolic diseases
JP2012511002A (ja) 2008-12-05 2012-05-17 メルク・シャープ・エンド・ドーム・コーポレイション アンジオテンシンｉｉ受容体アンタゴニストとしてのニトロオキシ誘導体
CA2749903C (en) 2009-01-23 2016-09-06 Jae Hyun Park Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same
CN103080095A (zh) 2010-04-19 2013-05-01 心脏林克斯股份公司 用于治疗血管和代谢疾病的携带氮氧化物给体的缬沙坦衍生物
EP2560634A1 (en) * 2010-04-23 2013-02-27 Piramal Enterprises Limited Nitric oxide releasing prodrugs of therapeutic agents
WO2011160974A2 (en) 2010-06-21 2011-12-29 Nicox S.A. Statin derivatives
JO3350B1 (ar) 2011-03-07 2019-03-13 Merck Sharp & Dohme مشتقات حلقية غير متجانسة محتوية على مجموعات أمينو أولية ومركبات داي أزينيومديولات
CA2897571C (en) 2013-01-21 2018-12-18 Apparao Satyam Nitric oxide releasing prodrugs of therapeutic agents containing at least one carboxylic acid group
CN103275074B (zh) * 2013-06-21 2016-08-10 黄冈鲁班药业股份有限公司 一种奥美沙坦衍生物及其制备方法
CN105820125B (zh) * 2015-01-09 2018-12-07 北京中医药大学 一种用于治疗高血压的化合物及其制备方法和用途
US10456405B2 (en) 2015-09-07 2019-10-29 Zhejiang Huahai Pharmaceutical Co., Ltd Nitric oxide-releasing prodrug molecule of substituted quinazolines
CN106800537B (zh) 2017-01-18 2019-02-01 广东隆赋药业股份有限公司 丁苯酞-替米沙坦杂合物及其制备方法和用途
CN108892624B (zh) * 2018-06-20 2020-12-15 重庆威鹏药业有限公司 沙库巴曲硝基氧衍生物及其制备方法和应用
CN114105881B (zh) * 2020-08-31 2024-01-26 沈阳海诺威医药科技有限公司 血小板聚集抑制剂及其制备方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69034103T2 (de) * 1989-06-14 2004-07-15 Smithkline Beecham Corp. Imidazoalkensäure
IT1311924B1 (it) * 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
WO2002015935A1 (fr) * 2000-08-25 2002-02-28 Takeda Chemical Industries, Ltd. Agents de reduction du fibrinogene
ITMI20011744A1 (it) * 2001-08-09 2003-02-09 Nicox Sa Farmaci per le vasculopatie

Also Published As

Publication number Publication date
WO2005011646A2 (en) 2005-02-10
HK1095093A1 (en) 2007-04-27
RU2006105804A (ru) 2007-09-20
NO20060900L (no) 2006-02-24
WO2005011646A3 (en) 2005-04-21
NZ544463A (en) 2009-10-30
IS2534B (is) 2009-08-15
DK1653950T3 (da) 2008-05-26
PL1653950T3 (pl) 2008-08-29
ATE383155T1 (de) 2008-01-15
JP2007500684A (ja) 2007-01-18
CN100496490C (zh) 2009-06-10
CA2534451A1 (en) 2005-02-10
DE602004011230T2 (de) 2009-01-02
ECSP066334A (es) 2006-07-28
SI1653950T1 (sl) 2008-06-30
ES2299861T3 (es) 2008-06-01
HRP20060084A2 (hr) 2006-04-30
PT1653950E (pt) 2008-04-11
MA27987A1 (fr) 2006-07-03
IL172703A0 (en) 2006-04-10
EP1653950A2 (en) 2006-05-10
CY1110447T1 (el) 2015-04-29
IS8332A (is) 2006-02-27
BRPI0413028A (pt) 2006-10-03
CN1832742A (zh) 2006-09-13
RU2374240C2 (ru) 2009-11-27
US20060276523A1 (en) 2006-12-07
PL379420A1 (pl) 2006-09-04
UA87983C2 (ru) 2009-09-10
DE602004011230D1 (de) 2008-02-21
EP1653950B1 (en) 2008-01-09
AU2004260830B2 (en) 2010-04-29
ZA200600856B (en) 2007-05-30
AR045145A1 (es) 2005-10-19
AU2004260830A1 (en) 2005-02-10
KR20060056352A (ko) 2006-05-24

Similar Documents

Publication Publication Date Title
MXPA06001263A (es) Derivados de nitrooxi de losartan, valsartan, candesartan, telmisartan, eprosartan y olmesartan como bloqueadores de receptor de angiotensina ii para el tratamiento de enfermedades cardiovasculares.
NL301145I2 (nl) Tirbanibulin
EP1902576A4 (en) SPEECH SYSTEM FOR TELECONFERENCES
NO2017019I2 (no) Enzalutamid eller et farmasøytisk akseptabelt salt derav
HK1105586A1 (en) Phthalazine derivatives as parp inhibitors
IL192948A0 (en) Novel pyridine derivatives
IL180736A0 (en) Hydantoin derivatives for the treatment of inflammatory disorders
WO2008074450A3 (en) Non-peptidic renin inhibitors nitroderivatives
IS7717A (is) Pýrídasínónafleiður sem PDF4-hemlar
MEP31408A (en) Specific binding agents to hepatocyte growth factor
TW200700406A (en) Novel thiophene derivatives
TW200716591A (en) Novel thiophene derivatives
TW200708511A (en) Novel thiophene derivatives
TW200716552A (en) Novel thiophene derivatives
TW200738725A (en) Unsaturated mTOR inhibitors
EP1759463A4 (en) SYSTEM FOR OPTIMIZING CELLULAR PHONE CALLS WITH MINIMUM SYSTEM OVERLOAD BY THE USER
TW200738670A (en) Novel thiophene derivatives
MX2007004699A (es) Derivados de indol y bencimidazol.
SG149831A1 (en) Benzimidazole derivatives
IL183599A0 (en) Novel hydantoin derivatives as metalloproteinase inhibitors
IL176942A0 (en) Imidazolo-5-yl-2-anilinopyrimidines as agents for the inhibition of cell proliferation
WO2006101867A3 (en) Treatment of inflammatory bowel disease
IL183667A0 (en) Novel hydantoin derivatives as metalloproteinase inhibitors
WO2009082526A3 (en) Ortho pyrrolidine, benzyl-substituted heterocycle ccr1 antagonists for autoimmune diseases & inflammation
WO2009106471A3 (en) Angiotensin ii receptor blocker derivatives

Legal Events

Date Code Title Description
FG Grant or registration